We are studying whether oral arsenic can help patients with low-risk myelodysplastic syndromes who haven't responded to other treatments. The trial aims to assess its safety and effectiveness over 12 weeks.
Health conditions and diseases that the clinical trial is designed to study and treat.
Low-risk Myelodysplastic Syndromes (MDS) are a group of disorders caused by poorly formed or dysfunctional blood cells, often leading to symptoms like fatigue, weakness, and an increased risk of infections. This condition can occur when the bone marrow does not produce enough healthy blood cells.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.